share_log

Tonix Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-Alyeska Investment Group, L.P.(9.99%),Alyeska Fund GP, LLC(9.99%), etc.

Tonix Pharmaceuticals | SC 13G：超過5%持股股東披露文件-Alyeska Investment Group, L.P.(9.99%),Alyeska Fund GP, LLC(9.99%)等

SEC announcement ·  02/14 15:56
Moomoo AI 已提取核心訊息
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have collectively reported beneficial ownership of 5,855,597 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing approximately 9.99% of the company's outstanding shares. The filing, made with the United States Securities and Exchange Commission, indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The ownership percentage is based on the current total of 58,614,593 outstanding shares of Tonix Pharmaceuticals, as reported in the company's Form 8-K filed on January 25, 2024. The report also includes a statement that the reporting persons hold warrants to purchase additional shares, but due to the terms of the Warrants, they can only exercise enough to maintain a 9.9% ownership stake. The filing was completed on February 14, 2024, by Jason Bragg, Chief Financial Officer of Alyeska Investment Group, L.P. and Alyeska Fund GP, LLC, and Anand Parekh individually.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have collectively reported beneficial ownership of 5,855,597 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing approximately 9.99% of the company's outstanding shares. The filing, made with the United States Securities and Exchange Commission, indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. The ownership percentage is based on the current total of 58,614,593 outstanding shares of Tonix Pharmaceuticals, as reported in the company's Form 8-K filed on January 25, 2024. The report also includes a statement that the reporting persons hold warrants to purchase additional shares, but due to the terms of the Warrants, they can only exercise enough to maintain a 9.9% ownership stake. The filing was completed on February 14, 2024, by Jason Bragg, Chief Financial Officer of Alyeska Investment Group, L.P. and Alyeska Fund GP, LLC, and Anand Parekh individually.
Alyeska Investment Group, L.P.、Alyeska Fund GP, LLC和Anand Parekh共同報告了5,855,597股Tonix Pharmicals Holding Corp. 普通股的實益所有權，約佔該公司已發行股份的9.99％。這份向美國證券交易委員會提交的文件表明，這些股票是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。所有權百分比基於Tonix Pharmicals目前在該公司於2024年1月25日提交的8-K表中公佈的58,614,593股已發行股票總額。該報告還包括一份聲明，稱申報人持有認股權證以購買更多股份，但根據認股權證的條款，他們只能行使足夠的權來維持9.9％的所有權。該文件由Alyeska Investment Group, L.P. 和 Alyeska Fund GP, LLC的首席財務官傑森·布拉格以及阿南德·帕雷克分別於2024年2月14日完成。
Alyeska Investment Group, L.P.、Alyeska Fund GP, LLC和Anand Parekh共同報告了5,855,597股Tonix Pharmicals Holding Corp. 普通股的實益所有權，約佔該公司已發行股份的9.99％。這份向美國證券交易委員會提交的文件表明，這些股票是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。所有權百分比基於Tonix Pharmicals目前在該公司於2024年1月25日提交的8-K表中公佈的58,614,593股已發行股票總額。該報告還包括一份聲明，稱申報人持有認股權證以購買更多股份，但根據認股權證的條款，他們只能行使足夠的權來維持9.9％的所有權。該文件由Alyeska Investment Group, L.P. 和 Alyeska Fund GP, LLC的首席財務官傑森·布拉格以及阿南德·帕雷克分別於2024年2月14日完成。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息